Overview

Webcast ImageWebcast
MannKind at JPMorgan Healthcare Conference (Replay)
01/14/15 at 1:30 p.m. PT

MannKind Corporation (Nasdaq:MNKD) is a biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Our lead investigational product candidate, AFREZZA® , is an ultra rapid-acting insulin. AFREZZA is in late stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia.

Featured Links


Receive E-mail AlertsE-mail Alert Icon
Alerts are e-mailed to you whenever certain new company information is posted to this site.
Sign-up Now!
MNKD (Common Stock)
ExchangeNASDAQ GM (US Dollar)
Price$5.75
Change (%) Stock is Up 0.18 (3.23%)
Volume4,268,500
Data as of 01/23/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore Press Releases
DateTitle 
01/12/15MannKind CEO Alfred Mann to Transition to Executive Chairman; COO and President Hakan Edstrom Appointed to CEO
Alfred Mann to Remain Focused on Development and Financing of Future Products of MannKind VALENCIA, Calif., Jan. 12, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), a biopharmaceutical-based technology company, today announced that Alfred Mann, the company's founder, retired from his role as Chief Executive Officer effective January 9, 2015 and will transition to Executive Chairman. Mr. Mann intends to remain engaged with the company in business matters, including those relating to... 
Printer Friendly Version
01/08/15MannKind Earns $50 Million in Milestone Payments From Sanofi
VALENCIA, Calif., Jan. 8, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced that it has earned a total of $50 million in milestone payments in connection with the satisfaction of manufacturing milestones specified in its collaboration and licensing agreement with Sanofi. Pursuant to the agreement, MannKind previously received a $150 million upfront payment and is eligible to earn up to $725 million in further development, regulatory and sales milestones, and is also eli... 
Printer Friendly Version
01/07/15MannKind Corporation to Present at the J.P. Morgan 2015 Healthcare Conference
VALENCIA, Calif., Jan. 7, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), focused on discovering, developing and commercializing therapeutic products for diabetes, announced today that it will present at the 33RD Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2015 at 1:30 PM (PST) at Westin St. Francis Hotel in San Francisco, California. Interested parties can access a link to the live webcast of the presentations from the News & Events section of the Com... 
Printer Friendly Version
11/25/14MannKind Corporation to Present at The 26th Annual Piper Jaffray Healthcare Conference
VALENCIA, Calif., Nov. 25, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), focused on discovering, developing and commercializing therapeutic products for diabetes, announced today that it will present at The 26th Annual Piper Jaffray Healthcare Conference on Tuesday, December 2, 2014 at 3:00 PM (ET) at the New York Palace Hotel in New York City. Interested parties can access a link to the live webcast of the presentations from the News & Events section of the Company's webs... 
Printer Friendly Version
Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.



Print Page Print | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts IR Contacts | Financial Tear Sheet Tear Sheet